B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

348.23 +1.73 (+0.50%)
Streaming Delayed Price Updated: 1:36 PM EDT, Sep 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
From BeOne Medicines Ltd.
Via Business Wire
News headline image
Earnings Preview: BeiGene ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
AppLovin, First Solar And Li Auto Are Among Top 10 Large Cap Losers Last Week (June 16-20): Are The Others In Your Portfolio? ↗
Top 10 worst performing large-cap stocks last week: APP, FSLR, JHX, ONC, GSK, ACN, ANET, LI, CPAY, MA. Reasons include short-sell report, tax bill, and market selloff. 
Via Benzinga
News headline image
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
From BeOne Medicines Ltd.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
From BeOne Medicines Ltd.
Via Business Wire
News headline image
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
From BeiGene, Ltd.
Via Business Wire
News headline image
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
From BeiGene, Ltd.
Via Business Wire
News headline image
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗
Via The Motley Fool
Topics Economy Law Enforcement
News headline image
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
From BeiGene, Ltd.
Via Business Wire
News headline image
Earnings Scheduled For May 14, 2025 ↗
 
Via Benzinga
News headline image
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
News headline image
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat ↗
BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 outlook and margin guidance. 
Via Benzinga
News headline image
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
News headline image
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
From BeiGene, Ltd.
Via Business Wire
News headline image
Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back ↗
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
News headline image
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial ↗
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy. 
Via Stocktwits
News headline image
Why Is Summit Therapeutics Stock Soaring On Wednesday? ↗
Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway. 
Via Benzinga
News headline image
BeiGene to Announce First Quarter 2025 Financial Results on May 7
From BeiGene, Ltd.
Via Business Wire
News headline image
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Forecasting The Future: 4 Analyst Projections For BeiGene ↗
 
Via Benzinga
News headline image
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit ↗
BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.